IOVANCE BIOTHERAPEUTICS, INC. 4

Chief Regulatory Officer Raj K. Puri had 9,766 RSUs vest into common stock and 4,478 shares withheld for taxes at Iovance Biotherapeutics, Inc. (IOVA).

On September 8, 2026, Iovance Biotherapeutics, Inc. Chief Regulatory Officer Raj K. Puri had 9,766 restricted stock units vest into an equal number of common shares, and simultaneously 4,478 shares of common stock were withheld by the issuer at a price of $8.70 per share to satisfy mandatory tax withholding obligations; these transactions are recorded as an RSU conversion (code M) and a tax withholding disposition (code F), not as open-market trading. Following these events, Puri’s direct ownership stood at 256,364 shares of common stock and 58,599 remaining RSUs (reflecting the unvested portion of a March 5, 2025 grant), which will continue to vest in equal quarterly installments. The transactions are routine equity compensation events with no net cash purchase or discretionary sale by the insider.

Filing Facts

CIK

1425205

Ticker

IOVA

Form

4

Source Type

fda

Accession

0001104659-26-106748

Alert Tier

5